The N-terminal region of the human papillomavirus L2 protein contains overlapping binding sites for neutralizing, cross-neutralizing and non-neutralizing antibodies

Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer

Núbia Muñóz, F. Xavier Bosch, Sílvia de Sanjosé et al. · New England Journal of Medicine · 2003 · 6.3K citations · Full text

Medicine, Oncology, Pathology +17

Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases

Suzanne M. Garland, Mauricio Hernández‐Ávila, Cosette M. Wheeler et al. · New England Journal of Medicine · 2007 · 1.9K citations

Medicine, Infectious Diseases, Preventive Medicine +17

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

Jorma Paavonen, Paulo Naud, Jorge Salmerón et al. · The Lancet · 2009 · 1.7K citations

Medicine, Gynecology, Oncology +17

Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

Diane M. Harper, Eduardo L. Franco, Cosette M. Wheeler et al. · The Lancet · 2006 · 1.6K citations · Full text

Veterinary Medicine, Immunology, Oncology +16

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

Jorma Paavonen, David Jenkins, F. Xavier Bosch et al. · The Lancet · 2007 · 1.3K citations

Veterinary Medicine, Immunology, Oncology +17